Why the study?
Does an ACE inhibitor or a thiazide diuretic provide better cardiovascular outcomes in patients with hypertension?
Does an ACE inhibitor or a thiazide diuretic provide better cardiovascular outcomes in patients with hypertension?
Answers are grounded in this paper and cite their sources.
This commentary discusses the conflicting results of the ALLHAT and ANBP2 trials regarding the comparative efficacy of ACE inhibitors versus diuretics in hypertension.
An ongoing debate during the past 2–3 months has centered on the results of two recent clinical trials in hypertension—the ALLHAT and ANBP2 trials. These apparently yielded different outcomes; in the American trial (ALLHAT), the use of a thiazide diuretic resulted in a better outcome with some cardiovascular end points compared to an ACE inhibitor. In the Australian trial (ANBP2), an ACE inhibitor was marginally (p=0.05) more effective in reducing end points than a diuretic (most of the benefit in men). In the following commentary, Dr. Jeffrey Cutler, the Senior Scientific Advisor to the Division of Epidemiology and Clinical Application of the National Heart, Lung, and Blood Institute, compares these two trials. Dr. Cutler has been involved in almost all of the major clinical hypertension trials in the United States over the last 20 years.—Marvin Moser, MD, Editor in Chief
No takes yet. Share an insight, caveat, or question.
Jeffrey A. Cutler (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: